全文获取类型
| 收费全文 | 2346322篇 |
| 免费 | 175031篇 |
| 国内免费 | 3319篇 |
专业分类
| 耳鼻咽喉 | 32049篇 |
| 儿科学 | 75891篇 |
| 妇产科学 | 62685篇 |
| 基础医学 | 348168篇 |
| 口腔科学 | 63620篇 |
| 临床医学 | 211339篇 |
| 内科学 | 457267篇 |
| 皮肤病学 | 51727篇 |
| 神经病学 | 185266篇 |
| 特种医学 | 88005篇 |
| 外国民族医学 | 489篇 |
| 外科学 | 353851篇 |
| 综合类 | 47508篇 |
| 现状与发展 | 12篇 |
| 一般理论 | 848篇 |
| 预防医学 | 182727篇 |
| 眼科学 | 54325篇 |
| 药学 | 175102篇 |
| 11篇 | |
| 中国医学 | 4575篇 |
| 肿瘤学 | 129207篇 |
出版年
| 2021年 | 18978篇 |
| 2019年 | 19537篇 |
| 2018年 | 27057篇 |
| 2017年 | 20357篇 |
| 2016年 | 22745篇 |
| 2015年 | 25638篇 |
| 2014年 | 36094篇 |
| 2013年 | 53958篇 |
| 2012年 | 74674篇 |
| 2011年 | 79407篇 |
| 2010年 | 47055篇 |
| 2009年 | 44565篇 |
| 2008年 | 74607篇 |
| 2007年 | 79476篇 |
| 2006年 | 80294篇 |
| 2005年 | 77777篇 |
| 2004年 | 74370篇 |
| 2003年 | 71690篇 |
| 2002年 | 69362篇 |
| 2001年 | 108738篇 |
| 2000年 | 111450篇 |
| 1999年 | 93494篇 |
| 1998年 | 26990篇 |
| 1997年 | 23658篇 |
| 1996年 | 24054篇 |
| 1995年 | 22715篇 |
| 1994年 | 20893篇 |
| 1993年 | 19712篇 |
| 1992年 | 72000篇 |
| 1991年 | 70069篇 |
| 1990年 | 68391篇 |
| 1989年 | 65663篇 |
| 1988年 | 60302篇 |
| 1987年 | 59125篇 |
| 1986年 | 55217篇 |
| 1985年 | 53004篇 |
| 1984年 | 39311篇 |
| 1983年 | 33396篇 |
| 1982年 | 19858篇 |
| 1979年 | 35866篇 |
| 1978年 | 25651篇 |
| 1977年 | 21230篇 |
| 1976年 | 20332篇 |
| 1975年 | 21816篇 |
| 1974年 | 26148篇 |
| 1973年 | 24802篇 |
| 1972年 | 23200篇 |
| 1971年 | 22037篇 |
| 1970年 | 20247篇 |
| 1969年 | 19315篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
241.
van der Heijden Amber A. W. A. de Bruijne Martine C. Nijpels Giel Hugtenburg Jacqueline G. 《International journal of clinical pharmacy》2019,41(4):963-971
International Journal of Clinical Pharmacy - Background Drug-related problems (DRP) following hospital discharge may cause morbidity, mortality and hospital re-admissions. It is unclear whether a... 相似文献
242.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献243.
244.
245.
246.
247.
Denise Lee Marcella D. Walker Hsin Yi Chen John A. Chabot James A. Lee Jennifer H. Kuo 《Surgery》2019,165(1):107-113
Background
Bone mineral density (BMD) has been found to improve after parathyroidectomy (PTX) in patients with primary hyperparathyroidism. There are few data on the effect of PTX on BMD in normocalcemic and normohormonal primary hyperparathyroidism.Methods
A retrospective analysis of 92 primary hyperparathyroidism patients who underwent PTX between 2004 and 2012 with pre- and post-PTX dual-energy x-ray absorptiometry was performed. Within-person changes in BMD pre- and post-PTX were analyzed using log linear mixed models, stratified by biochemical status.Results
Bone mineral density increased post-PTX in the whole cohort at the lumbar spine (+2.5%), femoral neck (+2.1%), and total hip (+1.9%) and decreased at the one-third radius (–0.9%). On comparison of BMD changes by profile, BMD increased in those with the typical profile at the lumbar spine (3.2%), femoral neck (2.9%), and total hip (2.9%) but declined at the one-third radius (–1.5%). In contrast, BMD improved only at the femoral neck (4.3%) in the normohormonal group and did not change at any site in the normocalcemic group. The typical group had a greater increase in BMD over time at the femoral neck and total hip compared with normocalcemic patients.Conclusion
Our results indicate that the skeletal benefit of PTX was attenuated in normocalcemic and normohormonal patients, suggesting that skeletal changes after PTX may depend on biochemical profile. 相似文献248.
Victoria A. Chang Dawn M. Meyer Brett C. Meyer 《Journal of stroke and cerebrovascular diseases》2019,28(1):163-166
Background
Acute stroke codes may be activated for anisocoria, but how often these codes lead to a final stroke diagnosis or alteplase treatment is unknown. The purpose of this study was to assess the frequency of anisocoria in stroke codes that ultimately resulted in alteplase administration.Methods
We retrospectively assessed consecutive alteplase-treated patients from a prospectively-collected stroke registry between February 2015 and July 2018. Based on the stroke code exam, patients were categorized as having isolated anisocoria [A+(only)], anisocoria with other findings [A+(other)], or no anisocoria [A?]. Baseline demographics, stroke severity, alteplase time metrics, and outcomes were also collected.Results
Ninety-six patients received alteplase during the study period. Of the 94 who met inclusion criteria, there were 0 cases of A+(only). There were 9 cases of A+(other) (9.6%). A+(other) exhibited higher baseline National Institutes of Health (NIH) Stroke Scale scores compared to A? (17 versus 7; P?=?.0003), and no additional differences in demographics or alteplase time metrics. Final stroke diagnosis and other outcome measures were no different between A+(other) and A?. Of the A+ patients without pre-existing anisocoria, 5 of 6 (83%) had posterior circulation events or diffuse subarachnoid hemorrhage.Conclusions
In this exploratory analysis, zero patients with isolated anisocoria received alteplase treatment. Anisocoria as a part of the neurologic presentation occurred in 10% of alteplase patients, and was strongly associated with a posterior circulation event. Therefore, we conclude that anisocoria has a higher likelihood of leading to alteplase treatment when identified in the presence of other neurologic deficits. 相似文献249.
Annals of Surgical Oncology - 相似文献